Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and ...

In November, Novavax CEO John C. Jacobs detailed the company’s efforts beyond its COVID-19 vaccine, including expanding ...

Explore Pfizer’s evolving pipeline strategy, expanding into oncology and obesity to drive growth beyond its COVID-19 success.

BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent of rapid development of novel biopharmaceuticals. Its diversified portfolio of oncology product ...

Pfizer Inc. has acquired exclusive rights to commercialize an obesity therapy in China, strengthening its push into the ...

Interest in the use and impacts of glucagon-like peptide-1 receptor agonists in rheumatology has exploded over the past year, a trend that appeared to crescendo at ACR Convergence 2025. There, ...

​Pfizer Inc. (NYSE: PFE) is among the Best Affordable Stocks Under $40 to Buy. On February 17, Pfizer Inc. (NYSE:PFE) announced positive results from its key BREAKWATER trial, which is testing ...

Johnson & Johnson is upgraded to Buy and Pfizer to Hold reflecting improved profitability outlooks post-Q4 2025 earnings.

The cardiology landscape is rapidly evolving. Novel risk factors and new tools are reshaping CV risk assessment and ...